Dova Pharmaceuticals, Inc. (DOVA) Given Consensus Recommendation of “Strong Buy” by Brokerages
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) has received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating. Dova Pharmaceuticals’ rating score has improved by 40.1% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price objective of $34.00 for the company, according to Zacks. Zacks has also given Dova Pharmaceuticals an industry rank of 103 out of 265 based on the ratings given to related companies.
Several research firms have recently commented on DOVA. Leerink Swann raised Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 target price for the company in a report on Tuesday, September 26th. Jefferies Group upped their target price on Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research lowered Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th.
Shares of Dova Pharmaceuticals (NASDAQ DOVA) opened at $30.09 on Friday. Dova Pharmaceuticals has a one year low of $16.98 and a one year high of $30.48.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). During the same quarter in the previous year, the business posted ($0.41) earnings per share. equities analysts expect that Dova Pharmaceuticals will post -1.51 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Dova Pharmaceuticals, Inc. (DOVA) Given Consensus Recommendation of “Strong Buy” by Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/02/dova-pharmaceuticals-inc-dova-given-consensus-recommendation-of-strong-buy-by-brokerages.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.